Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …
been available for a long time. Therefore, conventional chemotherapy is still considered the …
Advances and challenges in targeting FGFR signalling in cancer
IS Babina, NC Turner - Nature Reviews Cancer, 2017 - nature.com
Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …
[HTML][HTML] Genetic markers in triple-negative breast cancer
Z Sporikova, V Koudelakova, R Trojanec… - Clinical breast cancer, 2018 - Elsevier
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …
is characterized by the absence of estrogen, progesterone, and human epidermal growth …
Targeting FGFR signaling in cancer
The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary
conserved signaling cascade that regulates several basic biologic processes, including …
conserved signaling cascade that regulates several basic biologic processes, including …
Icariin‐induced inhibition of SIRT6/NF‐κB triggers redox mediated apoptosis and enhances anti‐tumor immunity in triple‐negative breast cancer
L Song, X Chen, L Mi, C Liu, S Zhu, T Yang… - Cancer …, 2020 - Wiley Online Library
Abnormal activation of the nuclear factor‐kappa B (NF‐κB) signaling pathway is closely
implicated in triple‐negative breast cancer growth, metastasis, and tumor immune escape. In …
implicated in triple‐negative breast cancer growth, metastasis, and tumor immune escape. In …
[HTML][HTML] Recent therapeutic trends and promising targets in triple negative breast cancer
SY Hwang, S Park, Y Kwon - Pharmacology & therapeutics, 2019 - Elsevier
Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
YK Chae, K Ranganath, PS Hammerman… - …, 2016 - pmc.ncbi.nlm.nih.gov
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase
signaling pathway that has a fundamental role in many biologic processes including …
signaling pathway that has a fundamental role in many biologic processes including …
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
BD Lehmann, JA Pietenpol - The Journal of pathology, 2014 - Wiley Online Library
Triple‐negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular
subtypes that respond differentially to chemotherapy and targeted agents. The absence of …
subtypes that respond differentially to chemotherapy and targeted agents. The absence of …
Triple-negative breast cancer and the potential for targeted therapy
JR Jhan, ER Andrechek - Pharmacogenomics, 2017 - Taylor & Francis
Breast cancer is composed of several well-recognized subtypes including estrogen receptor,
progesterone receptor and HER2 triple-negative breast cancer (TNBC). Without available …
progesterone receptor and HER2 triple-negative breast cancer (TNBC). Without available …
Targeted therapies for triple-negative breast cancer: combating a stubborn disease
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
cancers that have a poor clinical outcome. Although no approved targeted therapy is …